Insider Buying: Dr. Martens (LON:DOCS) Insider Purchases 192 Shares of Stock

Dr. Martens plc (LON:DOCS) insider Ije Nwokori bought 192 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The shares were purchased at an average cost of GBX 78 per share, for a total transaction of £149.76.

Ije Nwokori also recently made the following trade(s):

• On Thursday, December 11th, Ije Nwokori purchased 197 shares of Dr. Martens stock. The shares were purchased at an average cost of GBX 76 per share, with a total value of £149.72.
• On Tuesday, November 11th, Ije Nwokori purchased 176 shares of Dr. Martens stock. The shares were purchased at an average price of GBX 85 per share, for a total transaction of £149.60.

Dr. Martens Stock Down 0.6%

DOCS opened at GBX 75.15 on Thursday. The company has a debt-to-equity ratio of 127.27, a quick ratio of 1.13 and a current ratio of 2.85. The company has a market capitalization of £726.37 million, a PE ratio of 44.21, a P/E/G ratio of 6.40 and a beta of 0.11. The stock’s fifty day moving average is GBX 78.10 and its 200-day moving average is GBX 83.50. Dr. Martens plc has a one year low of GBX 43.02 and a one year high of GBX 100.87.

Dr. Martens (LON:DOCS) last announced its earnings results on Thursday, November 20th. The company reported GBX (0.90) earnings per share for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. On average, equities analysts predict that Dr. Martens plc will post 2.5809394 EPS for the current fiscal year.

Analyst Ratings Changes

DOCS has been the topic of a number of research reports. Berenberg Bank reiterated a “buy” rating on shares of Dr. Martens in a report on Thursday, November 27th. Peel Hunt restated a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 20th. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Dr. Martens presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 6,000.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.